ThermoFisher Scientific, Inc., bioMérieux SA and Danaher are Dominating the Global Antimicrobial Susceptibility Testing Market in 2020

Global Antimicrobial Susceptibility Testing Market is expected to grow with the CAGR of 5.7% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-antimicrobial-susceptibility-testing-market  

Global antimicrobial susceptibility testing market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.     

The major players dealing in global antimicrobial susceptibility testing market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance-

  • In April 2020, ThermoFisher Scientific Inc. added imipenem/relebactam ARIS HiQ to its automated and manual antimicrobial susceptibility testing portfolio which will act as treatment for urinary tract infections. It will also expand options for antimicrobial testing in clinical settings. This will propel the growth of the market in coming years.

 ThermoFisher Scientific, Inc. is the dominating player in global antimicrobial susceptibility testing market. The other key players existing in the market are BD, Synbiosis, Zhuhai DL Biotech Co., Ltd, Mast Group Ltd., HiMedia Laboratories, Bio-Rad Laboratories, Inc., Creative Diagnostics, Genefluidics, Inc.,  Rosco Diagnostica A/S, ERBA Group, Liofilchem S.r.l., Alifax S.r.l., MERLIN Gesellschaft für mikrobiologische Diagnostika mbH, bioMérieux SA, Merck KGaA, Danaher, Accelerate Diagnostics, Inc., NuMedii, Inc., and BacterioScan, Inc.

Antimicrobial Susceptibility Testing MarketThermoFisher Scientific, Inc.

ThermoFisher Scientific, Inc. headquartered in Delaware, the U.S. The company was established in 1977. The company is the world leader in serving science, delivering an unrivalled combination of innovative technologies, purchasing convenience and pharmaceutical services. The market focus products lie under Clinical diagnostics. The company is engaged in continuous development of antimicrobial susceptibility testing methods and related products.   

  • In August, ThermoFisher Scientific Inc.,   launched an automated reading and incubation system for AST, which is antimicrobial susceptibility testing to select an effective antibiotics for critically ill patients. The system will help provide accurate MIC results in microbiology laboratories. Hence, will help in the growth of the market.

The company has wide presence across Asia-Pacific, Europe, North America, South America and Middle East & Africa. The company has various subsidiaries like Thermo Scientific (Massachusetts, United States), Applied Biosystems (California, United States), Invitrogen (California, United States), among others.

bioMérieux SA

bioMérieux SA is headquartered in Lyon, France and was founded in 1963. The company is engaged in the production of in vitro diagnostic solutions such as systems, reagents, software and services for private and hospital laboratories for diagnosis of infectious disease. The market focus products lie under microbiology. The company is engaged in continuous development of antimicrobial susceptibility testing methods and related products.   

  • In July, bioMérieux SA announced the launch of biofire micoplasma, a rapid, and easy to use molecular biology test. This innovative test would generate the demand in the market and help the company to grow in coming years.

The company has wide presence across North America, South America, Europe, Middle East and Africa and Asia-Pacific. The company also has various subsidiary companies such as Argene SA (France), Invisible Sentinel (U.S.), Applied Maths (Belgium), bioMerieux UK Ltd. (UK), and bioMerieux, Inc. among others.

DANAHER

Danaher has its headquartered in Washington, United States and was founded in 1969. Danaher operates as a medical company, which designs, manufactures, and markets professional, medical, industrial and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The market focus products lie under diagnostics. The company is engaged in continuous development of antimicrobial susceptibility testing methods and related products.    

For instance-

  • In July, Cepheid, a subsidiary of Danaher launched a novel rapid molecular test for TB which can detect multi-drug resistance to first-line and second-line drugs simultaneously. The profiling can be achieved in less than 90 minutes. This will drive the antimicrobial testing market in the coming years.

The company has wide presence across North America, South America, Europe, Middle East/Africa, Asia & Pacific. The company has various subsidiary companies such  as Aquafine Corporation (California), Beckman Coulter Inc. (California), Cepheid (California), Leica Biosystems Imaging Inc. (California) among others.